

Outpatient Medical Injectable Infliximab Authorization Request Form Fax to 833-619-5745 (Medical Benefit Only)

Member Name:	DOB:			
Member UMI:				
Address:				
REQUESTING PHYSICIAN INFORMATION				
Physician Name:	NPI:			
Address:				
Office Contact: Phone	e Number:Fax Number:			
SITE OF CARE				
Place of Administration Name:	Name: NPI:			
Address:				
Place of Administration Type (please select one)				
☐ Home Infusion ☐ Office – Professional ☐ Ambulatory Infusion Suite – Professional ☐ Outpatient Hospital				
Is the site of care affiliated with a hospital or will the claim be billed as a facility claim? \square Yes \square No				
Drug Dispensing Information (please select one)				
□ Supplied by a Specialty Pharmacy (for Home Infusion, Office – Professional, or Ambulatory Infusion Suite – Professional) Name: NPI:				
☐ Buy & Bill (for Office – Professional or Outpatient Hospital administration)				
DRUG INFORMATION (please select one)				
PREFERRED for ALL indications	NON-PREFERRED**:			
Avsola Q5121	Remicade J1745 Renflexis Q5104 Has the member experienced a documented drug therapy failure			
Inflectra Q5103	or intolerance to the <u>preferred products?</u>			
	Avsola: ☐ Yes ☐ No Inflectra: ☐ Yes ☐ No			
**Medicare members currently established on a non-preferred therapy are not required to try a preferred option	**A non-preferred product will be considered when the member has a documented drug therapy failure after an adequate therapeutic trial, or intolerance, or contraindication to BOTH preferred products			

^{**}Please verify member's eligibility and benefits through the health plan**

DRUG INFORMATION (cont	tinued)			
Requested Drug Name:	Strength or Dose:			
Directions:	Quantity (# of doses/visits):			
CLINICAL INFORMATION				
Diagnosis code (ICD10):	Member weight:			
Diagnosis Description (check	one)			
Ankylosing Spondylitis	(AS)	Non-infectious Uveitis	Juvenile Rheumatoid Arthritis	
Crohn's Disease (CD)		Ulcerative Colitis (UC)	Psoriatic Arthritis (PsA)	
Rheumatoid Arthritis (RA) ** Is Infliximab being used in combination with Methotrexate?				
Other				
		vere disease?ed		
☐ New Start	☐ Continuation of Therapy			
	Date of l	ast infusion:		
	Has the member demonstrated disease stability or a beneficial response to therapy? \Box YES \Box NO			
Please attach all pertinent clinical information				
Attached:				

^{**}Please verify member's eligibility and benefits through the health plan**